TSC2

Across TCGA pan-cancer cohorts, TSC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TSC2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TSC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TSC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where TSC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.927	0.574	.007	45	view →
HNSC	OS	Median	IV	0.965	0.702	.001	43	view →
PDAC	OS	Median	II,III,IV	0.906	0.794	.009	9	view →
LSCC	DFS	Quartile	II,III,IV	0.805	1.000	.021	5	view →
LUAD	OS	Tertile	All	1.000	0.950	.040	2	view →
GBM	DFS	Median	All	0.849	0.649	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TSC2–CCRCC (OS)

Open the CCRCC breakdown →